title: Evaluation of safety of insulin degludec on undergoing total colonoscopy using continuous glucose monitoring.
abstract: OBJECTIVE
  There is little information regarding how to use insulin degludec (D) when diabetic patients are preparing for total colonoscopy (TCS).
  
  
  METHODS
  A total of 12 patients with type 2 diabetes treated with insulin D and scheduled to undergo TCS were enrolled in the present study. A continuous glucose monitoring device was attached to each patient for 4 days, from two evenings before TCS to the morning after the procedure. The patients fasted for 24 h, starting after 18.00 h the day before TCS. Insulin D was only discontinued the morning of the day TCS was carried out.
  
  
  RESULTS
  No patients experienced hypoglycemia during the daytime fasting period (08.00-18.00 h the day of TCS); the hypoglycemic index, mean glucose level, and standard deviation were 0, 141.3 ± 31.5 mg/dL and 15.6 ± 6.5 mg/dL. The mean glucose level and standard deviation during the daytime fasting period were significantly lower than during the daytime control period (08.00-18.00 h the day before TCS; P = 0.003, P = 0.001, respectively). The mean fasting glucose and fasting plasma glucose levels were significantly correlated (r = 0.78, P = 0.002), as were both the mean glucose level and standard deviation during the daytime control period, and the change in the mean glucose level (fasting period minus control period; r = -0.79, P = 0.002, and r = -0.69, P = 0.01, respectively).
  
  
  CONCLUSIONS
  Patients can safely undergo TCS when insulin D is discontinued only once on the day of the procedure.
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Soichi
authors.initials: S
authors.lastname: Takeishi
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Mori
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Nobutoshi
authors.initials: N
authors.lastname: Fushimi
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Hachiya
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Takayuki
authors.initials: T
authors.lastname: Yumura
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Shun
authors.initials: S
authors.lastname: Ito
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Shibuya
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Noritsugu
authors.initials: N
authors.lastname: Ohashi
authors.affiliation: Department of Endocrinology and Diabetes Ichinomiyanishi Hospital Aichi Japan.
authors.forename: Hiromi
authors.initials: H
authors.lastname: Kawai
mesh_terms: D000368:Aged; D003113:Colonoscopy / Q000379:methods*; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000188:drug therapy*; D005215:Fasting / Q000009:adverse effects*; D005260:Female; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D049528:Insulin, Long-Acting / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic
chemical_list: D049528:Insulin, Long-Acting; C571886:insulin degludec; D005947:Glucose
keywords: Continuous glucose monitoring; Insulin degludec; Total colonoscopy